Monday, March 17, 2025 | 12:59 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Covid-19 crisis: Indian drug companies yet to get nod to market remdesivir

The USFDA granted remdesivir an emergency use authorization for the treatment of hospitalized patients with severe Covid-19

pharmacy, drugs, medicine, pharma companies, pharmaceuticals
Premium

Government officials feel that since the APIs as well as the key starting material (KSM) would be made in India, the pricing of the drug would become affordable.

Sohini Das Mumbai
While US-based Gilead Sciences has been granted authorisation for restricted emergency use of remdesivir to treat Covid-19 patients, Indian players are yet to receive approval to market the drug.

Moreover, it is learnt that the firms haven’t yet approached the National Pharmaceutical Pricing Regulator (NPPA) formally to discuss pricing of the drug, which will be used on hospitalised patients.

Sources said the pharma companies are in touch with various government departments and there was a video conference meeting recently. However, no decision on pricing has been taken yet. As for dosage, sources say it will be decided by the Indian Council of

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in